These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 7728390)

  • 21. New approaches to the therapy of autoimmune diseases: rheumatoid arthritis as a paradigm.
    Moreland LW; Heck LW; Sullivan W; Pratt PW; Koopman WJ
    Am J Med Sci; 1993 Jan; 305(1):40-51. PubMed ID: 8416681
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The pharmacokinetics and human anti-mouse antibody response in rheumatoid arthritis patients treated with a chimeric anti-CD4 monoclonal antibody.
    Choy EH; Schantz A; Pitzalis C; Kingsley GH; Panayi GS
    Br J Rheumatol; 1998 Jul; 37(7):801-2. PubMed ID: 9714366
    [No Abstract]   [Full Text] [Related]  

  • 23. Successful use of adalimumab for treating rheumatoid arthritis with autoimmune sensorineural hearing loss: two birds with one stone.
    Morovic Vergles J; Radic M; Kovacic J; Salamon L
    J Rheumatol; 2010 May; 37(5):1080-1. PubMed ID: 20439536
    [No Abstract]   [Full Text] [Related]  

  • 24. Use of monoclonal antibodies in vivo as a therapeutic strategy for alloimmune or autoimmune reactivity: the Besançon experience.
    Herve P; Racadot E; Wendling D; Rumbach L; Tiberghien P; Cahn JY; Flesch M; Wijdenes J
    Immunol Rev; 1992 Oct; 129():31-55. PubMed ID: 1464420
    [No Abstract]   [Full Text] [Related]  

  • 25. Biologic agents in the therapy of inflammatory rheumatic diseases, including therapeutic antibodies, cytokines, and cytokine antagonists.
    Kalden JR
    Curr Opin Rheumatol; 1994 May; 6(3):281-6. PubMed ID: 8060762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New aspects in the treatment of immunomediated diseases.
    Shoenfeld Y; Ferrone S; Bombardieri S
    Clin Exp Rheumatol; 1991; 9(6):663-73. PubMed ID: 1684923
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Anti-CD4 therapy in treatment of rheumatoid arthritis--have the die been cast?].
    Keysser G; Alpermann U; Burmester GR
    Z Rheumatol; 1998 Oct; 57(5):320-5. PubMed ID: 9864838
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Rheumatic diseases in general practice. II. Therapeutic possibilities with special reference to rheumatoid arthritis].
    Pedersen C; Hansen TM; Pedersen PA; Halberg P; Frølund F; Lorenzen I
    Ugeskr Laeger; 1983 Apr; 145(15):1174-7. PubMed ID: 6603699
    [No Abstract]   [Full Text] [Related]  

  • 29. Chimeric CD4 monoclonal antibody cM-T412 as a therapeutic approach to rheumatoid arthritis.
    van der Lubbe PA; Reiter C; Breedveld FC; Krüger K; Schattenkirchner M; Sanders ME; Riethmüller G
    Arthritis Rheum; 1993 Oct; 36(10):1375-9. PubMed ID: 8216397
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-CD4 treatment of patients with rheumatoid arthritis. Is there still a place for this treatment principle in RA?
    Kalden JR
    Clin Exp Rheumatol; 1994; 12 Suppl 11():S67-9. PubMed ID: 7768057
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BAFF and rheumatic autoimmune disorders: implications for disease management and therapy.
    Bosello S; Pers JO; Rochas C; Devauchelle V; De Santis M; Daridon C; Saraux A; Ferraccioli GF; Youinou P
    Int J Immunopathol Pharmacol; 2007; 20(1):1-8. PubMed ID: 17346422
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic strategies using monoclonal antibodies in autoimmune disease.
    Pankewycz O; Strom TB; Kelley VE
    Curr Opin Immunol; 1989 Apr; 1(4):757-63. PubMed ID: 2508704
    [No Abstract]   [Full Text] [Related]  

  • 33. [New perspectives in the treatment of rheumatoid disease].
    Laurindo IM; Cossermelli W
    Rev Hosp Clin Fac Med Sao Paulo; 1993; 48(1):1-3. PubMed ID: 8235262
    [No Abstract]   [Full Text] [Related]  

  • 34. Functional Defects of Treg Cells: New Targets in Rheumatic Diseases, Including Ankylosing Spondylitis.
    Miao J; Zhu P
    Curr Rheumatol Rep; 2018 Apr; 20(5):30. PubMed ID: 29663162
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases.
    Wilder RL
    Ann Rheum Dis; 2002 Nov; 61 Suppl 2(Suppl 2):ii96-9. PubMed ID: 12379637
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunomodulators.
    Schrieber L
    Agents Actions Suppl; 1988; 24():254-64. PubMed ID: 3055878
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Monoclonal antibody therapy].
    Schäffner G; Kabelitz D
    Dtsch Med Wochenschr; 2001 Jul; 126(30):851-6. PubMed ID: 11512284
    [No Abstract]   [Full Text] [Related]  

  • 38. Monoclonal antibody therapy.
    Park JW; Smolen J
    Adv Protein Chem; 2001; 56():369-421. PubMed ID: 11329858
    [No Abstract]   [Full Text] [Related]  

  • 39. Experimental basis of innovative therapies of rheumatoid arthritis.
    Shiroky JB; Yocum DE; Wilder RL; Klippel JH
    Concepts Immunopathol; 1989; 7():106-44. PubMed ID: 2477153
    [No Abstract]   [Full Text] [Related]  

  • 40. [The current outlook in the therapy of autoimmune diseases].
    Sebastiani GD; Passiu G
    Ann Ital Med Int; 1992; 7(2):95-101. PubMed ID: 1467130
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.